BioSenic SA

Report Publication Announcement • Aug 29, 2025

BioSenic provides an update on the preparation of the annual accounts and annual report for the financial year ending on 31 December 2024

BioSenic announces delay on the preparation of the annual accounts and annual report for the financial year ending on 31 December 2024

Saintes, Belgium, 29 August 2025, 6 PM – BioSenic (Euronext Brussels and Paris: BIOS) announces that, due to the unavailability of the annual accounts for the financial year ending 31 December 2024 of its subsidiary Medsenic SAS, currently in liquidation, BioSenic will finalize and close its own annual accounts and annual board report for the financial year ending 31 December 2024 on the basis of Medsenic's adjusted accounts dated 30 June 2024.

Discussions are active with the company's statutory auditor to close the consolidated annual accounts for the financial year ending on 31 December 2024 with a view on publishing the 2024 full year results and submitting the consolidated annual accounts and annual report to the ordinary general meeting for approval.

In light of the above, the publication of the full year results and the 2024 annual report is postponed to 29 September 2025 and the ordinary general meeting to 30 October 2025. The financial calendar on the company's website will be adapted in consequence. BioSenic can however not exclude to postpone further if circumstances oblige.

Biosenic remains committed to open communication with its investors and other stakeholders and will provide timely updates on any material developments.

About BioSenic

BioSenic is a biotechnology company with long-standing scientific and clinical legacy in orthopedics and regenerative therapies specialising in the clinical development of therapies in bone and cartilage repair.

BioSenic still owns some interests in its clinical assets ALLOB and JTA but is now focussing on a joint development with 4Moving Biotech on a GLP-1 based, disease-modifying therapy for veterinary use, specifically in post-ligament surgery recovery in dogs. Biosenic is also focusing on other new potential partnerships.

BioSenic is based in Avenue Léon Champagne 3, 1480 Saintes (Tubize), Belgium. Further information is available at http://www.biosenic.com.

For further information, please contact:

BioSenic SA

Finsys Management SRL, represented by its permanent representative Jean-Luc Vandebroek, managing director ad interim investorrelations@biosenic.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the company or, as appropriate, the company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.